Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States

References

• Swerdlow SH, Harris NL, Campo E. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 220–226.
   Google Scholar
• Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998;9:717–720.
   PubMed Web of Science ®Google Scholar
• Horning SJ. Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol 1993;20:75–88.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009;27:1202–1208.
   PubMed Web of Science ®Google Scholar
• Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447–8452.
   PubMed Web of Science ®Google Scholar
• Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006;24:1582–1589.
   PubMed Web of Science ®Google Scholar
• Sacchi S, Pozzi S, Marcheselli L, et al. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer 2007;109:2077–2082.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203–1210.
   PubMed Web of Science ®Google Scholar
• Jacobson CA, Freedman AS. First-line treatment of indolent lymphoma: axing CHOP? Lancet 2013;381:1163–1165.
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1997;15:1110–1117.
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Sinha R, Byrtek M, et al. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer 2014; 120:1830–1837.
   PubMed Web of Science ®Google Scholar
• D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265–2281.
   PubMed Web of Science ®Google Scholar
• Berger ML, Mamdani M, Atkins D, et al. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part I. Value Health 2009;12:1044–1052.
   PubMed Web of Science ®Google Scholar
• Cox E, Martin BC, Van Staa T, et al. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II. Value Health 2009;12:1053–1061.
   PubMed Web of Science ®Google Scholar
• Johnson ML, Crown W, Martin BC, et al. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III. Value Health 2009;12:1062–1073.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417–1423.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725–3732.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Pulsoni A, Perrotti A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004;22:2654–2661.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Seymour J, Feugier P, et al. Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study. Ann Oncol 2011;22(Suppl. 4): Abstract 89.
   Google Scholar
• Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 2013; 31:1506–1513.
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Kahl BS, et al. Open-label, randomized, noninferiority study of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of advanced indolent NHL or MCL: the BRIGHT study. Blood 2014;23:2944–2952.
   Web of Science ®Google Scholar
• Martin P, Jung S, Johnson J, et al. CALGB 50803 (Alliance): a phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. Hematol Oncol 2013;31(Suppl. 1): Abstract 063.
   Google Scholar
• Fowler NH, Neelapu SS, Hagemeister FB, et al. Lenalidomide and rituximab for untreated indolent lymphoma: final results of a phase II study. Blood 2012;120(Suppl 1): Abstract 901.
   Google Scholar
• Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients. J Clin Oncol 2003;21:897–906.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Estey E, Glassman A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 2005;105:4573–4575.
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Neelapu SS, Samaniego F, et al. 10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: results of a randomized study. J Clin Oncol 2014;32(Suppl. 1): Abstract 8528.
   Google Scholar
• Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol 2008;26:5165–5169.
   PubMed Web of Science ®Google Scholar
• Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 2013;31:3272–3278.
   PubMed Web of Science ®Google Scholar
• Wagner-Johnston N, Link BK, Taylor M, et al. Risk factors for early transformation of follicular lymphoma: report from the National LymphoCare Study. Blood 2009;114(Suppl. 1): Abstract 2698.
   Google Scholar
• Kimby E, Björkholm M, Gahrton G, et al. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 1994;5(Suppl. 2):S67–S71.
   PubMed Web of Science ®Google Scholar
• Paus R, Haslam IS, Sharov AA, et al. Pathobiology of chemotherapy-induced hair loss. Lancet Oncol 2013;14:e50–e59.
   PubMed Web of Science ®Google Scholar
• Williams J, Wood C, Cunningham-Warburton P. A narrative study of chemotherapy-induced alopecia. Oncol Nurs Forum 1999;26: 1463–1468.
   PubMedGoogle Scholar
• Richer MC, Ezer H. Living in it, living with it, and moving on: dimensions of meaning during chemotherapy. Oncol Nurs Forum 2002;29:113–119.
   PubMedGoogle Scholar
• Kissane DW, Grabsch B, Love A, et al. Psychiatric disorder in women with early stage and advanced breast cancer: a comparative analysis. Aust NZ J Psychiatry 2004;38:320–326.
   PubMed Web of Science ®Google Scholar
• Luoma ML, Hakamies-Blomqvist L. The meaning of quality of life in patients being treated for advanced breast cancer: a qualitative study. Psychooncology 2004;13:729–739.
   PubMed Web of Science ®Google Scholar
• Freedman TG. Social and cultural dimensions of hair loss in women treated for breast cancer. Cancer Nurs 1994;17:334–341.
   PubMed Web of Science ®Google Scholar
• McGarvey EL, Baum LD, Pinkerton RC, et al. Psychological sequelae and alopecia among women with cancer. Cancer Pract 2001;9:283–289.
   PubMedGoogle Scholar